Sponsors / OMER
OMER

Omeros Corporation

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
8Trials in this database
11Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesNCT02222545Omeros CorporationPhase 2Completed2020-01-30Actual
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721NCT02682407Omeros CorporationPhase 2Terminated2020-08-25Actual
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeNCT03205995Omeros CorporationPhase 3Terminated2021-02-02Actual
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyNCT03608033Omeros CorporationPhase 3Terminated2024-01-12Actual
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMANCT05855083Omeros CorporationPhase 2Recruiting2025-12Estimated
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabNCT05972967Omeros CorporationPhase 2Completed2024-10-10Actual
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNNCT06209736Omeros CorporationPhase 2Recruiting2026-01Estimated
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaNCT06298955Omeros CorporationPhase 2Active not recruiting2026-12Estimated

Latest recorded trial changes

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

NCT02682407 · Omeros Corporation

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy subjects with treatment related adverse events (AE). Measure: Cohort 4: Proportion of IgAN patients of Asian descent with treatment related AEs. Measure: Cohort 4: Change from baseline in serum and urine complement component levels.

+ After

Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE). Measure: Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs. Measure: Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels.

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

54 participants (planned)

+ After

31 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Dec 2020

+ After

25 Aug 2020

Recruitment status changed

− Before

Recruiting

+ After

Terminated

Check registry source